Financière de Tubize SA (TUB.BR)
EUR 138.8
(-0.86%)
EUR 138.8
(-0.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 123.65 Million EUR | 41.82% |
| 2022 | 87.18 Million EUR | 316.4% |
| 2021 | 20.93 Million EUR | -38.88% |
| 2020 | 34.25 Million EUR | -60.83% |
| 2019 | 87.46 Million EUR | -39.28% |
| 2018 | 144.03 Million EUR | -26.38% |
| 2017 | 195.65 Million EUR | -26.24% |
| 2016 | 265.26 Million EUR | -14.94% |
| 2015 | 311.84 Million EUR | 46.03% |
| 2014 | 213.54 Million EUR | -15.67% |
| 2013 | 253.23 Million EUR | -13.73% |
| 2012 | 293.53 Million EUR | -8.36% |
| 2011 | 320.31 Million EUR | -6.06% |
| 2010 | 340.97 Million EUR | -7.0% |
| 2009 | 366.63 Million EUR | -5.97% |
| 2008 | 389.92 Million EUR | -5.77% |
| 2007 | 413.79 Million EUR | 72.19% |
| 2006 | 240.3 Million EUR | 104.48% |
| 2005 | 117.52 Million EUR | -4.22% |
| 2004 | 122.69 Million EUR | -21.41% |
| 2003 | 156.12 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 31.68 Million EUR | 0.0% |
| 2023 FY | 123.65 Million EUR | 41.82% |
| 2023 Q2 | 48.59 Million EUR | 0.0% |
| 2023 Q4 | 123.65 Million EUR | 0.0% |
| 2022 Q2 | 46.14 Million EUR | 0.0% |
| 2022 FY | 87.18 Million EUR | 316.4% |
| 2022 Q4 | 87.18 Million EUR | 0.0% |
| 2021 FY | 20.93 Million EUR | -38.88% |
| 2021 Q4 | 20.93 Million EUR | 0.0% |
| 2021 Q2 | 703 Thousand EUR | 0.0% |
| 2020 FY | 34.25 Million EUR | -60.83% |
| 2020 Q4 | 34.25 Million EUR | 0.0% |
| 2020 Q2 | 32.61 Million EUR | 0.0% |
| 2019 Q2 | 87.23 Million EUR | 0.0% |
| 2019 Q4 | 87.46 Million EUR | 0.0% |
| 2019 FY | 87.46 Million EUR | -39.28% |
| 2018 Q4 | 144.03 Million EUR | 0.0% |
| 2018 FY | 144.03 Million EUR | -26.38% |
| 2018 Q2 | 140.71 Million EUR | 0.0% |
| 2017 Q2 | 211.74 Million EUR | 0.0% |
| 2017 FY | 195.65 Million EUR | -26.24% |
| 2017 Q4 | 195.65 Million EUR | 0.0% |
| 2016 FY | 265.26 Million EUR | -14.94% |
| 2016 Q2 | 262.11 Million EUR | 0.0% |
| 2016 Q4 | 265.26 Million EUR | 0.0% |
| 2015 FY | 311.84 Million EUR | 46.03% |
| 2015 Q2 | 169.3 Million EUR | 0.0% |
| 2015 Q4 | 311.84 Million EUR | 0.0% |
| 2014 Q4 | 213.54 Million EUR | 0.0% |
| 2014 Q2 | 239.21 Million EUR | 0.0% |
| 2014 FY | 213.54 Million EUR | -15.67% |
| 2013 FY | 253.23 Million EUR | -13.73% |
| 2013 Q4 | 253.23 Million EUR | 0.0% |
| 2013 Q2 | 282.55 Million EUR | 0.0% |
| 2012 Q4 | 293.53 Million EUR | 0.0% |
| 2012 Q2 | 320.31 Million EUR | 0.0% |
| 2012 FY | 293.53 Million EUR | -8.36% |
| 2011 Q2 | 306 Million EUR | 0.0% |
| 2011 FY | 320.31 Million EUR | -6.06% |
| 2011 Q4 | 320.31 Million EUR | 0.0% |
| 2010 Q2 | 340.85 Million EUR | 0.0% |
| 2010 FY | 340.97 Million EUR | -7.0% |
| 2010 Q4 | 340.97 Million EUR | 0.0% |
| 2009 Q4 | 366.63 Million EUR | 0.0% |
| 2009 FY | 366.63 Million EUR | -5.97% |
| 2008 FY | 389.92 Million EUR | -5.77% |
| 2007 FY | 413.79 Million EUR | 72.19% |
| 2006 FY | 240.3 Million EUR | 104.48% |
| 2005 FY | 117.52 Million EUR | -4.22% |
| 2004 FY | 122.69 Million EUR | -21.41% |
| 2003 FY | 156.12 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -1688.92% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 5.648% |
| Adocia SA | 31.87 Million EUR | -287.983% |
| Aelis Farma SA | 13.08 Million EUR | -845.338% |
| Biophytis S.A. | 15.84 Million EUR | -680.176% |
| Advicenne S.A. | 24.37 Million EUR | -407.241% |
| genOway Société anonyme | 14.45 Million EUR | -755.147% |
| IntegraGen SA | 5.97 Million EUR | -1967.798% |
| Medesis Pharma S.A. | 6.42 Million EUR | -1824.161% |
| Neovacs S.A. | 3.71 Million EUR | -3230.981% |
| NFL Biosciences SA | 3.62 Million EUR | -3315.106% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -1723.116% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -3635.533% |
| Sensorion SA | 13.22 Million EUR | -834.812% |
| Theranexus Société Anonyme | 5.01 Million EUR | -2365.022% |
| TME Pharma N.V. | 2.78 Million EUR | -4339.862% |
| Valbiotis SA | 13.7 Million EUR | -802.029% |
| TheraVet SA | 1.48 Million EUR | -8226.649% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -504.114% |
| argenx SE | 402.79 Million EUR | 69.302% |
| BioSenic S.A. | 32.26 Million EUR | -283.245% |
| Celyad Oncology SA | 9.97 Million EUR | -1139.228% |
| DBV Technologies S.A. | 38.74 Million USD | -219.136% |
| Galapagos NV | 1.56 Billion EUR | 92.083% |
| Genfit S.A. | 105.92 Million EUR | -16.738% |
| GeNeuro SA | 20.13 Million EUR | -513.956% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -1335.789% |
| Innate Pharma S.A. | 132.29 Million EUR | 6.532% |
| Inventiva S.A. | 101.59 Million EUR | -21.711% |
| MaaT Pharma SA | 22.46 Million EUR | -450.412% |
| MedinCell S.A. | 77.77 Million EUR | -58.995% |
| Nanobiotix S.A. | 95.74 Million EUR | -29.152% |
| Onward Medical N.V. | 25.69 Million EUR | -381.166% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -392.13% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -109.296% |
| Oxurion NV | 19.73 Million EUR | -526.521% |
| Pharming Group N.V. | 228.28 Million EUR | 45.835% |
| Poxel S.A. | 53.9 Million EUR | -129.402% |
| GenSight Biologics S.A. | 34.72 Million EUR | -256.063% |
| Transgene SA | 26.51 Million EUR | -366.305% |
| UCB SA | 6.56 Billion EUR | 98.116% |
| Valneva SE | 341.14 Million EUR | 63.754% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -2619.379% |